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Abstract
We introduce a method for estimating incidence curves of several co-circulating infectious pathogens, where each infection
has its own probabilities of particular symptom profiles. Our deconvolution method utilizes weekly surveillance data on
symptoms from a defined population as well as additional data on symptoms from a sample of virologically confirmed
infectious episodes. We illustrate this method by numerical simulations and by using data from a survey conducted on the
University of Michigan campus. Last, we describe the data needs to make such estimates accurate.
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Introduction
Timely and accurate estimates of influenza virus infection
incidence rates in a population are difficult to obtain because most
infectious episodes are unaccounted for, while influenza-like illness
can have a variety of etiologies other than influenza virus infection.
Manycountriesuse sentinel surveillancesystemstoascertainrates of
medical consultations associated with influenza-like illness [1,2],
and these data typically track the influenza epidemic curve although
they cannot provide information about absolute infection rates
without additional data on sensitivity and specificity over time.
Serological surveillance can permit robust estimates of incidence
rates in a population, although it can be costly and has rarely been
employed in the US. To date the literature only contains one
serological study of influenza infection in the US during the 2009
H1N1 pandemic [3]. Under a number of assumptions, sentinel
surveillance data can be combined with virologic surveillance to
estimate infection rates using a multiplier-type approach [4].
Here we propose an alternative approach to estimating age-
specific infection incidence rates in a population based on
syndromic surveillance data. The idea is that different infections
generate different distributions of symptom profiles for symptom-
atic individuals, and data on reported symptom profiles can be
‘‘deconvolved’’ to estimate the underlying incidence of various
infections. For example, among children with acute respiratory
illness (ARI), fever is predictive of influenza virus infection
(hereafter referred to as influenza) as the etiology [5]. The
proportion of febrile cases among individuals with ARI during a
time period when influenza incidence is high is expected to be
greater compared to the time period when influenza incidence is
low. Data on symptomatic and febrile cases in age-stratified
random population samples combined with an estimate of the
proportion of influenza cases who develop fever can therefore
potentially be used to infer influenza incidence during various time
periods. More generally, using data on symptom profile distribu-
tions combined with symptom data collected through surveillance,
one can estimate the symptomatic incidence attributable to each
infection; the latter estimate is obtained using the Expectation-
Maximization algorithm [6,7]. Similar considerations, though
involving different estimation methodology for symptoms and
causes of death appeared in [8].
In this paper we present the deconvolution (estimation) process
in detail and describe the data needs for making such estimates
accurate. We test the effect of deconvolution on simulated
incidence and symptom profile curves. Additionally, we apply it
to syndromic data collected during the declining period of an
influenza outbreak on the University of Michigan campus.
Methods
Ethics Statement
The study from which symptom profile data were obtained was
approved by the Institutional Review Board at the University of
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minimal risk’’ classification (http://clinicaltrials.gov/ct2/show/
NCT00490633).
1. Multinomial model
Suppose there are m different pathogens causing infection in a
population. Throughout this paper by ‘‘population’’ we denote a
group of people assumed to be homogeneous in the sense than the
distribution (probability) of symptoms associated with each of the
various circulating pathogens does not change in time for the
infected people in this population group. Correspondingly the
estimation method for disease incidence is restricted to such a
population for which symptom data is gathered.
Let the (unknown) symptomatic incidences of those infections in
the population on week t be I1
t,...,Im
t (we assume that no co-
infections occur). Let Popbe the total population size, and let
pi
t~
Ii
t
Pop
be the (time dependent) probability that a randomly
selected person becomes symptomatic with infection i on week t.
Let S1,...,SN be the set of possible symptom profiles observed
in patients. For instance if there are k possible symptoms then one
can take N~2k{1and the profiles are just the non-empty subsets
of 1,::,k fg . Use of this large number of profiles may lead to small
counts of the numbers of people experiencing each symptom
profile, so more parsimonious sets of symptom profiles may be
advantageous.
For each infection i let d(i)~(di
1,...di
N)be the probabilities of
particular symptom profiles for a person with that infection. For
identifiability of different infections we assume that the matrix
D~(di
j)has rank m, which in particular implies that mƒN and
that there is no infection for which the distribution of symptom
profiles can be expressed as a linear combination of the other
symptom profile distributions. Moreover we assume that for each
i,
X
j
di
j~1 ð Þ
Thus we are estimating symptomatic incidence, namely infections
for which one of the chosen symptom profiles is present.
Additional data on the proportion of individuals with each
infection who are ‘‘asymptomatic’’ (do not exhibit any of the
specified profiles) can allow one to estimate full incidence
(symptomatic and asymptomatic incidence of the corresponding
infection). For influenza, various estimates of the asymptomatic
fraction exist in the literature [9,10,11]. A separate study tailored
for the specific population and the circulating influenza strain
should render a more accurate estimate of the asymptomatic
fraction. Note that under this approach, estimation of the full
incidence for the etiology of interest does not require data on the
asymptomatic proportion for the other etiologies.
Suppose we have a weekly report from Qtindividuals on week t
on their symptoms during the preceding week. The weekly data
can be reduced to a vector (Qt
1,...,Qt
N,Qt
AS) where Qt
j is the
number of persons with symptom profile Sj on week t, Qt
AS is the
number of asymptomatic persons and
X
1ƒjƒN
Qt
jzQt
AS~Qt
For each week t let Xt
ij be the (unobserved) number of people
among the Qt responders with infection i reporting symptom
profile Sjon week t (1ƒiƒm,1ƒjƒN). Thus
Qt
j~
X
i
Xt
ij
Moreover let Xt
AS be the number of asymptomatic persons. For a
randomly chosen person among the Qt responders, the probability
that he/she has infection i and reports symptom profile Sj (falls
into the category Xt
ij)i spt
iji. The probability that he/she is
asymptomatic is pt
AS~1{
P m
i~1
pt
i. Therefore the distribution of the
(observed) symptom counts (Qt
1,...,Qt
N,Qt
AS) is multinomial with
size Qt and the parameters
((pi
t):(di
j),pt
AS) ð1Þ
where (pt
i):(di
j) is a vector by matrix multiplication.
2. Symptom profile distributions
Equation (1) shows that the syndromic data alone cannot
identify the number of symptomatic individuals with each
infection. Therefore additional data on symptom profiles for
various infections are needed for the inference process. More
precisely, we assume that for each infection i we have data on
symptoms from Ni symptomatic individuals with infection i. Let
the observed counts of symptom profiles for those individuals be
(Oi
1,...,Oi
N),
X
Oi
j~Ni ð  Þ
Here the distribution of (Oi
1,...,Oi
N) is multinomial of size Ni and
parameters (di
1,...,di
N). In this section we describe how such
counts can be obtained from data; in the next section we describe
the inference process using the symptom surveillance data and the
symptom profile distribution data from equation (**).
Information about the distribution of symptoms for influenza
can be obtained during the course of an epidemic, or from
previous studies. We used the distribution of reported symptoms of
individuals with influenza confirmed by real-time polymerase
chain reaction (RT-PCR) in a community-based study [12].
Household contacts were recruited after index cases living in their
household presented for medical care with influenza-like symp-
toms. A contact was deemed infected if at least one RT-PCR test
was positive out of the 3 tests conducted during a 7-day follow-up
period. A contact was deemed having fever if the maximal
recorded tympanic temperature was 37.8uC or above. 118
influenza positive contacts in [12] had a presence of at least one
of the following four signs or symptoms: fever, cough, runny nose,
sore throat. We have examined the following two choices of
symptom profiles for the inference process and estimated their
distributions using data for those 118 individuals:
Choice 1:
1: Fever
2: No feverz1 of cough, runny nose, sorethroat ðÞ
3: No feverz2 of cough, runny nose, sore throat ðÞ
4: No feverzcoughzrunny nosezsore throat
ð2aÞ
Choice 2:
1: Fever
2: No feverzat least 1 of cough, runny nose, sore throat ðÞ
ð2bÞ
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not associated with influenza may be quite specific to the location
and the circulating respiratory viruses. One may be able to use
symptom surveillance data itself during a period when one knows
that the percent of flu among symptomatic individuals is very low
to suggest that almost all symptoms are attributable to non-flu
causes. Thus overall counts of symptom profiles reported by all
symptomatic individuals during that period give an estimate of the
non-flu symptom profile distribution. In this case that period
should also be removed from subsequent inference of influenza
incidence.
3. Inference process
3.1 EM iterations. Estimation of the parameters (pt
i)and (di
j)
can be done with the aid of the Expectation Maximization (EM)
algorithm [6,7,13] which iterates in the space of parameters
(pt
i)and (di
j) increasing the likelihood of observations (Qt
j,Oi
j) with
each iteration. Specifically let (pt
i(n))and (di
j(n))be the values of the
parameters after n EM iterations. To understand the iterative
process, denote for any parameters (p,d) the expectation of the
variable Xt
ij conditional on the observations Qt
j [13]:
E(Xt
ijjQt,p,d)~Qt
j: pt
i:di
j P
k
pt
k:dk
j
ð3Þ
The parameter values after the next EM iteration are given by
pt
i(nz1)~
1
Qt
X
j
E(Xt
ijjQt,p(n),d(n)) ð4Þ
and
di
j(nz1)~
P
t
E(Xt
ijjQt,p(n),d(n))zOi
j
P
t
P
k
E(Xt
ikjQt,p(n),d(n))zNi
ð5Þ
3.2 Inference Method 1. Several inference methods for the
model’s parameters are possible, and their robustness for a given
data set can be tested by the SEM algorithm [14], as well as by
bootstrapping. Similarly our inference process involves a choice of
certain symptom profiles for symptomatic individuals – e.g. the
one given by equation (2a) or (2b). Assessing the robustness of each
estimation method should also aid in the model selection for the
inference process.
Method 1 essentially assumes that the distribution of symptoms
is known. This deconvolution method based on equations (3) and
(4) was introduced in the optics literature [15,16] and subsequently
used in the epidemiological literature [13,17,18]:
Fix the initial estimate of the symptom profile distribution
^ d di
j~
Oi
j
Ni
Using this estimate, iterate in the parameters (pt
i) using equation
(4) (keeping the parameters (di
j) constant). Such iterates will
converge to the unique maximum likelihood estimate (^ p pt
i) for the
incidence parameters conditional on the parameters (^ d di
j) (see
section S1) regardless of the initial choice of non-zero initial
conditions.
3.3 Inference Method 2. Other inference methods involve
iterations in all of the model’s parameters (pt
i) and (di
j)-t h el a t t e ri s
generally known as ‘‘blind deconvolution’’ in the optics literature
[19]. The advantage of those methods over Method 1 is that they
allow to update the symptom profile distributions from the initial,
data-derived estimate (^ d di
j) by increasing the likelihood of all
observations (Qt
j,Oi
j). However given the lack of identifiability of
the parameters using observations (Qt
i) alone as specified by equation
(1), iterations in the symptom profile distribution parameters might
move them further away from their true value and worsen the
incidence curve estimates if the counts (Ni) are too small.
Several inference methods involving EM iterations in all the
parameters are possible, such as starting from an estimate in
Method 1 and using both equations (4) and (5) for subsequent
iterations. We have found that the classical EM scheme is fairly
robust for sufficiently large data sets:
Iterate all the parameters simultaneously using both equations
(4) and (5) in each step until convergence. An initial condition used
in this paper corresponded to expected weekly incidence 1 for each
infection in the survey sample (Qt:pt
i(0)~1).
4. Testing the deconvolution process by numerical
simulations
To test the deconvolution process we generated synthetic weekly
incidence curves both for influenza and non-influenza symptom-
atic cases over a 22-week period. The influenza incidence curve
corresponds to an epidemic with basic reproductive number 1.35
and the serial interval distribution with mean 2.6 days [20]
truncated at 7 days in a homogeneous population of 3,000,000.
We assumed that each week the number of individuals filling
out the symptom survey is random, Poisson distributed with mean
5000. For our simulations, we used both choices of the symptom
profiles described by equations (2a) and (2b), with their distribution
for symptomatic flu cases estimated from the data in [12].
Similarly, for illustration purposes we have generated the non-flu
symptom profile distribution for our simulations using the data
from [21] (see section 5 of the methods).
We used weekly synthetic incidence and distribution of
symptom profiles for flu and non-flu cases as described above to
perform the following independent 3-step simulations:
1. Generate the (weekly) symptom count curves using the given
incidence curves, symptom profile distributions and the weekly
number of survey respondents.
2. Assume that the estimate of the symptom profile distribution
dflu is obtained from data on 500 symptomatic flu cases. Re-
estimate the influenza symptom profile distribution by
multinomial binning of size 500 with the initial distribution
dflu. For non-flu symptoms, use the simulated symptom data
from the first 3 weeks and the last 3 weeks (weeks 20–22) of the
epidemic for an estimate the non-flu symptom profile
distribution. During that period there are 2055 expected
symptomatic cases given the incidence curves used in
simulations and 99.6% of them are non-flu cases.
3. Using the symptom data in step 1 for weeks 4–19 and the re-
estimates of the symptom profile distributions from step 2,
apply the deconvolution scheme from the corresponding
method; the output of the deconvolution process is an estimate
of incidence between weeks 4–19.
We wish to point out that the accuracy of the deconvolution
process depends not just on the number of individuals of survey
but also on the level of circulation of influenza as well as other
symptom causing pathogens in the community. Generally,
Estimating Incidence Using Symptom Data
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specific to influenza (primarily fever) in the survey are significantly
larger than the magnitude of the noise in the corresponding counts
for non-influenza symptomatic cases in the survey. In section S3
we perform various sensitivity analyses for the accuracy of the
deconvolution process (Figures S1, S2 and S4).
5. University of Michigan outbreak
We have used symptom surveillance data from a randomized
controlled trial of non-pharmaceutical interventions for preventing
transmission of influenza collected in February–March 2008 on
the University of Michigan campus [21]. With 1,000 individuals
initially recruited, the weekly number of survey respondents
ranged from 830 to 902. The eight weeks in the symptom
surveillance data represent a period after an apparent peak of a
seasonal influenza outbreak on the wider campus, as can be seem
from data on influenza positive tests and ILI consultations on the
campus medical facilities. The latter data suggest that flu
circulation during the last two of the eight weeks was particularly
low (figure S6 in section S5); surveillance data for those last two
weeks in the survey was used to assess the non-flu symptom profile
distribution. This symptom profile data from the last two weeks,
available for 642 symptomatic individuals was combined with
symptom data for the 118 RT-PCR positive household contacts of
flu cases, as specified in section 2 of the methods to assess the
influenza outbreak during weeks 1–6 in the survey period.
Weekly symptom profile counts attributable to influenza cases in
the survey were estimated to be quite low, of the same magnitude
as the noise (departure from expected values) in the symptom
profile counts attributable to non-flu cases. As result, weekly
estimates of flu incidence for such a small sample size in addition
to having wide confidence bounds are also generally upwardly
biased because they cannot go below 0. Consequently we have
combined all the surveillance data and were only able to estimate
the cumulative flu attack rate during the surveillance period, which
the bootstrap simulations have shown to be unbiased.
Results
1. Symptom profile distributions
Figure 1A plots the distribution of symptom profiles (as defined
in equation (2a) in the Methods) for flu cases taken from [12], as
described in section 3.1 of the methods. For our simulations we use
the symptom profile distribution for non-flu cases obtained from
the data in [21] (Figure 1B) – see also figure S5 in section S4.
Figure 1 suggests that fever is much more common for flu vs.
non-flu cases, and one non-fever symptom only (cough, runny
nose, or sore throat) is much more common for non-flu vs. flu
cases.
2. Synthetic incidence and symptom data deconvolution
2.1 Synthetic incidence curves. We have generated
synthetic incidence curves for flu and non-flu symptomatic cases
as described in the Methods; those curves are plotted in Figure 2.
2.2 Symptom profiles (2a). We have performed 600 3-step
simulations as specified in section 4 of the methods, both for
Method 1 and Method 2. Figure 3 plots two samples of 5
deconvolved influenza symptomatic incidence curves against the
original one (black) between weeks 4–19. One sample is for
Method 1 and another is for Method 2.
The cumulative number of symptomatic influenza cases
between weeks 4 and 19 was 993,693. For Method 1, for the
sample of 600 deconvolved symptomatic influenza incidence
curves, their cumulative incidences have mean 978,266, with 95%
of them falling between 762,556 and 1,197,579. For Method 2, the
mean is 1,004,402, with the 95% range between 823,519
and1,185,116. We see that Method 2 gives a somewhat sharper
estimate than Method 1 in this scenario.
2.3 Symptom profiles (2b). Figure 4 plots a sample of 5
deconvolved influenza symptomatic incidence curves against the
original one (black) between weeks 4–19, where symptom profiles
(2b) and deconvolution Method 2 were used.
The cumulative number of symptomatic influenza cases
between weeks 4 and 19 was 993,693. For the sample of 600
deconvolved symptomatic influenza incidence curves, their
cumulative incidences have mean 1,011,040, with 95% of them
falling between 793,340 and 1,209,297. We see that the estimates
are somewhat better using symptom profiles (2a) than (2b) in this
scenario.
3. University of Michigan outbreak
Figure 5 plots the weekly percentage of cases with fever among the
symptomatic cases during weeks 1–8 in the survey data from [21].
This percentage declined towards the end of the survey period,
Figure 1. Distribution of symptom profiles for flu (A) and non-flu (B) symptomatic cases, inferred from data in [12] and [21]. Profile
description is given in equation (2a).
doi:10.1371/journal.pone.0023380.g001
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the deconvolution process: flu (black), non-flu (red).
doi:10.1371/journal.pone.0023380.g002
Figure 3. Two samples of 5 deconvolved influenza symptomatic incidence curves (as described in section 4 of the Methods) against
the original one (black). (A) Method 1 deconvolution. (B) Method 2 deconvolution.
doi:10.1371/journal.pone.0023380.g003
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statistically significant: for example during the first3 weeks, 221/1555
(14.21%) of symptomatic individuals in the survey had fever; during
the next 3 weeks, 108/1004 (10.76%) of symptomatic individuals had
fever (OR 1.37, p-value 0.011 for the Fisher exact test).
The cumulative symptomatic attack rate of influenza during the
first 6 weeks was estimated to be 15.3%; however the 95%
confidence bounds were wide (2.2%,28.6%), suggesting that a
larger survey sample size is needed for an accurate estimate.
Discussion
Timely estimates of the progression of an influenza epidemic are
difficult to obtain. Currently available surveillance methods render
a limited assessment of the epidemic’s growth patterns while
serological surveillance is not commonly employed. Here we
propose an alternative method to estimate incidence based on
syndromic surveillance from population samples on regular times
intervals. Such surveillance (e.g. [22]), combined with estimates of
Figure 4. A sample of 5 deconvolved influenza symptomatic incidence curves (as described in section 4 of the Methods) against the
original one (black) for symptom profiles (2b), deconvolution method 2.
doi:10.1371/journal.pone.0023380.g004
Figure 5. Weekly percent of cases with fever among the symptomatic cases in the survey from [21].
doi:10.1371/journal.pone.0023380.g005
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cases may, in principle, render an accurate estimate of the
influenza incidence curve via the deconvolution process. We have
proposed a collection of symptom profiles to be used in the
deconvolution process, suggested how the corresponding symptom
profile distributions can be estimated from data and tested the
robustness of our method by numerical simulations. We wish to
point out that while we restricted our methodology to influenza-
like symptoms, it could in principle be adapted to estimation of
incidence of other types of diseases (e.g. enteric infections),
particularly if the infection of interest has a profile of symptoms
which largely sets it apart from other related infections (similarly to
the presence of fever, which is much more common for flu than for
other respiratory infections).
The key potential limitation of our method is the ability to
accurately estimate the distribution of symptom profiles for
influenza and non-influenza cases. Estimate of the flu incidence
is particularly sensitive to an estimate of the non-flu symptom
profile distribution because there are many more symptomatic
non-flu cases compared to the number of symptomatic flu cases in
a survey, so a misattribution of a certain percentage of non-flu
cases to flu is magnified relative to the flu data. Since the
distribution of symptom profiles for non-flu cases may be specific
to the given population, we propose to consider a time period in
the surveillance data when very little influenza circulation is
known to have taken place and use the symptom surveillance data
for that period for an estimate of the symptom profile distribution
for non-influenza cases. In this way, large sample size for the
surveillance data would also ensure a more accurate estimate of
the non-flu symptom profile distribution. Additionally, larger
samples increase the size of the symptomatic counts attributable to
influenza both in absolute terms and also relative to the noise in
such counts attributable to non-flu cases, further improving the
accuracy of the deconvolution process.
An additional potential issue with the symptom profile
distribution for non-flu symptomatic cases is that it might change
in time. The latter might occur due to an outbreak of a particular
respiratory agent, such as human rhinovirus, coronavirus, or
respiratory syncytial virus. The symptom profile distribution of
these infections might be different from the overall distribution for
symptomatic non-flu cases. One way to deal with this is to include
this agent into the list of infections whose incidence is estimated
through the deconvolution process. Alternatively, one may stick
with flu and symptomatic non-flu cases as the two infectious
profiles and use the excess fever approach (symptom profiles given
by equation (2b)). The latter might still be robust because fever is
much more common for flu than for non-flu cases and excess fever
attributable to flu when flu circulation is sufficiently high should be
larger than excess fever attributable to the potential difference in
the probability of fever given non-flu symptoms during different
time periods. This issue is examined through simulations in section
S3, where a large non-flu outbreak with ‘‘atypical’’ symptoms is
added as an unobserved component (Figure S3).
For the influenza symptom profile distribution, the most accurate
estimates should be obtained using data for each specific (evolving)
influenza season. Here for illustration purposes we have used data
from [12] onRT-PCRpositivehouseholdcontactsrecruitedwhen a
householdindexinfluenzacase sought medicalcare.Itisknownthat
the accuracy of the PCR test is correlated with symptom
presentation [23]. While three RT-PCR tests were administered
on each household contact in [12], it is possible that some infected
householdcontactshavetestednegative,andthisgroup iscorrelated
with a weaker presentation of symptoms. Due to a relatively small
sample size in [12] we did not attempt to derive age-stratified
estimates of the symptom profile distribution. Some difference in
symptom profile distribution for seasonal influenza A and B cases is
possible (see section S2), though no statistically significant difference
could bedetectedforthe smallsampleofcaseswheresub-typingwas
performed. We believe that larger studies involving serology may
render more accurate, age-stratified assessment of the syndrome
distribution for seasonal influenza.
We have employed the above method for the data from a
seasonal influenza outbreak on the University of Michigan campus.
Those estimates have several potential limitations. The survey was
not initially designed for our estimation method, with its size being
too small for accurate estimates of influenza incidence. Data on
symptom profilesfor influenzaused inthe deconvolutionprocess for
the University of Michigan campus is obtained from a different
population in [12]. Our assumption, based on the campus medical
facilities data, that the influenza outbreak has waned towards the
end of the study period may not be representative of the whole
University of Michigan campus. Therefore our estimates for the
University of Michigan outbreak are mostly given for illustrative
purposes. A careful study design should be used to avoid some of
those issues. Such design should perhaps involve the recruitment of
a large number of individuals (larger than what is needed for a
weekly survey) with a commitment from them to complete a certain
number of surveys when prompted during the study period. The
latter should decrease the correlation between the weekly symptom
reports and increase the percent of weekly recruits who fill out a
report, taking away from the recruitment bias when participation
might be correlated with symptom presentation. Finally, serologic
data if available could validate the syndrome-based estimation of
infection attack rates.
Supporting Information
Section S1 Convexity of the log likelihood function.
(DOC)
Section S2 Influenza A and B symptom profiles.
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Section S3 Numerical simulations for the deconvolution
process.
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Section S4 Symptom profile distribution for PCR-
negative, symptomatic household contacts.
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Section S5 Influenza incidence proxy on the University
of Michigan campus.
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Figure S1 Two samples of 5 deconvolved influenza
symptomatic incidence curves (as described in section
S3) against the original one (black). (A) Method 1
deconvolution. (B) Method 2 deconvolution.
(TIF)
Figure S2 A sample of 5 deconvolved influenza symp-
tomatic incidence curves (as described in section S3)
against the original one (black). Symptom profiles (2b),
Method 2.
(TIF)
Figure S3 Adding an ‘‘unobserved’’ non-flu outbreak
with atypical symptoms (as described in section S3).
Symptomatic influenza incidence (black), ‘‘regular’’ non-flu
incidence (red) and ‘‘outbreak’’ non-flu incidence (dashed red).
(TIF)
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outbreak with atypical symptoms (as described in
section S3) on the deconvolution process. A sample of 5
deconvolved influenza symptomatic incidence curves against the
original one (black). Symptom profiles (2b), Method 2. Flu and
non-flu incidence curves given by Figure S3.
(TIF)
Figure S5 Symptom profile distribution for PCR nega-
tive, symptomatic household contacts from [12] (A). Non-
flu symptom profile distribution from the main body of the text (B).
(TIF)
Figure S6 Weekly incidence proxy on the University of
Michigan campus, inferred from survey and virological
testing data in [21].
(TIF)
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